Literature DB >> 12655701

[Effect of glycyrrhizin on anti-tuberculosis drug-induced hepatitis].

Naoki Miyazawa1, Hiroshi Takahashi, Yasuhiro Yoshiike, Takashi Ogura, Yuji Watanuki, Masamichi Sato, Nobumasa Kakemizu, Yasushi Yamakawa, Chol-han U, Hideto Goto, Shigeki Odagiri.   

Abstract

In cases in which hepatotoxicity developed during anti-tuberculosis chemotherapy, the rapid recovery of liver function is essential for the completion of the anti-tuberculosis chemotherapy protocol. Glycyrrhizin (Stronger Neo-Minophagen C: SNMC) is widely used in Japan for the treatment of patients with drug eruption or chronic hepatitis. However, a consensus on the clinical effects of glycyrrhizin for the treatment of anti-tuberculosis drug-induced hepatitis has not yet been reached. We studied 24 cases who showed abnormal liver function test results while undergoing anti-tuberculosis chemotherapy and who were treated with or without glycyrrhizin. We then compared recovery periods of liver function among both groups. The time required for liver function normalization in the patients who received glycyrrhizin (SNMC, 40 ml daily, intravenously) was 15.1 +/- 4.5 days and the time required for normalization in the non-glycyrrhizin group was 15.2 +/- 5.2 days. The difference was not significant and the fact indicated that glycyrrhizin is not useful for the treatment of anti-tuberculosis drug-induced hepatitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655701

Source DB:  PubMed          Journal:  Kekkaku        ISSN: 0022-9776


  2 in total

1.  Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: a retrospective analysis.

Authors:  Zenya Saito; Yugo Kaneko; Akira Kinoshita; Yusuke Kurita; Kyuto Odashima; Tsugumi Horikiri; Yutaka Yoshii; Aya Seki; Yoshitaka Seki; Hiroshi Takeda; Kazuyoshi Kuwano
Journal:  BMC Infect Dis       Date:  2016-11-11       Impact factor: 3.090

2.  Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China.

Authors:  Yu Chen; Peng Ye; Chongwu Ren; Pengfei Ren; Zheng Ma; Lin Zhang; Wenliang Zhou; Changjie Jiang
Journal:  Open Med (Wars)       Date:  2018-03-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.